## **Core Concept**
Bevacizumab is a recombinant humanized monoclonal antibody used in the treatment of various cancers. It targets a specific protein involved in tumor angiogenesis. The mechanism of action of bevacizumab is closely related to its role in inhibiting the growth of new blood vessels that tumors need to grow.

## **Why the Correct Answer is Right**
Bevacizumab works by specifically binding to **vascular endothelial growth factor A (VEGF-A)**, preventing it from interacting with its receptors on endothelial cells. This interaction is crucial for the formation of new blood vessels (angiogenesis) that tumors exploit to secure their nutrient and oxygen supply for growth and metastasis. By inhibiting VEGF-A, bevacizumab effectively cuts off the tumor's blood supply, slowing down its growth. This mechanism is particularly relevant in the treatment of cancers known to have high levels of VEGF-A.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not provided, assuming incorrect based on the lack of information.
- **Option B:** Not provided, assuming incorrect based on the lack of information.
- **Option C:** Not provided, assuming incorrect based on the lack of information.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that bevacizumab is used in combination with other chemotherapy agents for the treatment of various cancers, including colorectal, lung, breast, and renal cancers. It's also important to note that bevacizumab can have significant side effects, including increased risk of bleeding and thrombotic events. A classic clinical correlation is its use in treating **metastatic colorectal cancer** in combination with chemotherapy, showing improved survival rates.

## **Correct Answer:** D. Monoclonal antibody against VEGF.